NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Boland MV, Ervin AM, Friedman D, et al. Treatment for Glaucoma: Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr. (Comparative Effectiveness Reviews, No. 60.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Treatment for Glaucoma: Comparative Effectiveness

Treatment for Glaucoma: Comparative Effectiveness [Internet].

Show details

Appendix CEvidence Tables

Evidence Table 1. Systematic review evidence I (MS Word, 65K)

Evidence Table 2. Systematic review evidence II (MS Word, 69K)

Evidence Table 3. Risk of bias for RCTs (MS Word, 67K)

Evidence Table 4. KQ1 medical population characteristics (MS Word, 51K)

Evidence Table 5. KQ 1 medical outcomes (MS Word, 52K)

Evidence Table 6. KQ 3 24-hour studies (MS Word, 50K)

Evidence Table 7. KQ 4 medical population (MS Word, 54K)

Evidence Table 8. KQ 4 medical outcomes (MS Word, 55K)

Evidence Table 9. KQ5 (MS Word, 49K)

Evidence Table 10. Risk of bias for observational studies (MS Word, 53K)

Evidence Table 11. KQ 6 medical I (MS Word, 57K)

Evidence Table 12. KQ6 medical II (MS Word, 58K)

Evidence Table 13. KQ1 surgical population, visual acuity and visual impairment (MS Word, 49K)

Evidence Table 14. KQ1 surgical Interventions (MS Word, 49K)

Evidence Table 15. KQ1 surgical outcomes (MS Word, 49K)

Evidence Table 16. KQ3 surgical population characteristics (MS Word, 59K)

Evidence Table 17. KQ3 surgical interventions (MS Word, 58K)

Evidence Table 18. KQ6 surgical I (MS Word, 60K)

Evidence Table 19. KQ6 surgical II (MS Word, 59K)

Evidence Table 20. KQ3 and KQ4 medical vs. surgical (MS Word, 46K)

Evidence Table 21. KQ2 (MS Word, 54K)

References

1.
Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17(8):667–73. [PubMed: 19092464]
2.
Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. 2004:CD004399. [PubMed: 15846712]
3.
Chai C, Loon SC. Meta-analysis of viscocanalostomy versus trabeculectomy in uncontrolled glaucoma. J Glaucoma. 2010;19(8):519–27. [PubMed: 20179632]
4.
Cheng JW, Wei RL. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther. 2008;30(4):622–32. [PubMed: 18498911]
5.
Cheng JW, Xi GL, Wei RL, Cai JP, Li Y. Efficacy and tolerability of nonpenetrating glaucoma surgery augmented with mitomycin C in treatment of open-angle glaucoma: a meta-analysis. Can J Ophthalmol. 2009;44(1):76–82. [PubMed: 19169318]
6.
Cheng JW, Xi GL, Wei RL, Cai JP, Li Y. Efficacy and tolerability of nonpenetrating filtering surgery in the treatment of open-angle glaucoma: a meta-analysis. Ophthalmologica. 2010;224(3):138–46. [PubMed: 19738394]
7.
Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol. 2008;92(6):729–34. [PubMed: 18460539]
8.
Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447–56. [PMC free article: PMC2724035] [PubMed: 19684868]
9.
Fung AT, Reid SE, Jones MP, Healey PR, McCluskey PJ, Craig JC. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br. J. Ophthalmol. 2007;91(1):62–8. [PMC free article: PMC1857560] [PubMed: 16956912]
10.
Hodge WG, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol. 2008;92(1):7–12. [PubMed: 18156371]
11.
Honrubia F, Garcia-Sanchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93(3):316–21. [PMC free article: PMC2639645] [PubMed: 19019922]
12.
Jampel HD, Lubomski LH, Friedman DS, et al. Treatment of coexisting cataract and glaucoma (Structured abstract). 2003.
13.
Kirwan JF, Rennie C, Evans JR. Beta radiation for glaucoma surgery. Cochrane Database Syst Rev. 2009;(2):CD003433. [PubMed: 19370589]
14.
Li N, Chen X-M, Zhou Y, Wei M-L, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: Meta-analysis of randomized controlled trials. Clinical and Experimental Ophthalmology: Clin. Exp. Ophthalmol. 2006;34(8):755–64. [PubMed: 17073898]
15.
Liu HN, Chen XL, Li X, Nie QZ, Zhu Y. Efficacy and tolerability of one-site versus two-site phaco-trabeculectomy: a meta-analysis of randomized controlled clinical trials. Chin Med J (Engl). 2010;123(15):2111–5. [PubMed: 20819551]
16.
Loon SC, Liew G, Fung A, Reid SE, Craig JC. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clin Experiment Ophthalmol. 2008;36(3):281–9. [PubMed: 18412600]
17.
Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005;331(7509):134. [PMC free article: PMC558697] [PubMed: 15994659]
18.
Minckler DS, Vedula SS, Li TJ, Mathew MC, Ayyala RS, Francis BA. Aqueous shunts for glaucoma. Cochrane Database Syst Rev. 2006;(2):CD004918. [PMC free article: PMC4292853] [PubMed: 16625616]
19.
Rolim de Moura Christiane R, Augusto Paranhos Jr, Richard Wormald. Laser trabeculoplasty for open angle glaucoma. Laser Trabeculoplasty for Open Angle Glaucoma. In: Rolim De Moura Christiane R, Augusto Paranhos Jr, Richard Wormald, editors. Cochrane Database of Systematic Reviews: Reviews. 4. 4. Vol. 2007. John Wiley & Sons, Ltd; Chichester, UK: 2007. [PubMed: 17943806] [Cross Ref]
20.
Vass C, Hirn C, Sycha T, et al. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2007;(4) [PubMed: 17943780]
21.
Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev. 2005;(4):CD002897. [PubMed: 16235305]
22.
Wormald R, Wilkins MR, Bunce C. Post-operative 5-Fluorouracil for glaucoma surgery. Cochrane Database Syst Rev. 2001;(3):CD001132. [PubMed: 11686977]
23.
Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2001;85(8):983–90. [PMC free article: PMC1724079] [PubMed: 11466259]
24.
Berry DP Jr, Van Buskirk EM, Shields MB. Betaxolol and timolol. A comparison of efficacy and side effects. Arch Ophthalmol. 1984;102(1):42–5. [PubMed: 6367723]
25.
Berson FG, Cohen HB, Foerster RJ, Lass JH, Novack GD, Duzman E. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure. Arch Ophthalmol. 1985;103(3):379–82. [PubMed: 3883972]
26.
Chiselita D, Antohi I, Medvichi R, Danielescu C. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia. 2005;49(3):39–45. [PubMed: 16408674]
27.
Parrish RK 2nd, Feuer WJ, Schiffman JC, Lichter PR, Musch DC. Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. Am J Ophthalmol. 2009;147(4):717–24. e1. [PMC free article: PMC2714658] [PubMed: 19152871]
28.
Cillino S, Zeppa L, Di Pace F, et al. E-PTFE (Gore-Tex(registered trademark)) implant with or without low-dosage mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial. Acta Ophthalmol. 2008;86(3):314–21. [PubMed: 17995980]
29.
Das JC, Sharma P, Chaudhuri Z, Bhomaj S. A comparative study of small incision trabeculectomy avoiding tenon’s capsule with conventional trabeculectomy. Ophthalmic Surg Lasers. 2002;33(1):30–6. [PubMed: 11820660]
30.
de Jong LA. The Ex-PRESS glaucoma shunt versus trabeculectomy in open-angle glaucoma: a prospective randomized study. Adv Ther. 2009;26(3):336–45. [PubMed: 19337705]
31.
D’Eliseo D, Pastena B, Longanesi L, Grisanti F, Negrini V. Comparison of deep sclerectomy with implant and combined glaucoma surgery. Ophthalmologica. 2003;217(3):208–11. [PubMed: 12660485]
32.
Diggory P, Cassels-Brown A, Vail A, Hillman JS. Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol. 1998;82(2):146–9. [PMC free article: PMC1722479] [PubMed: 9613379]
33.
Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23(3):385–94. [PubMed: 16912020]
34.
el Sayyad F, el-Rashood A, Helal M, Hisham M, el-Maghraby A. Fornix-based versus limbal-based conjunctival flaps in initial trabeculectomy with postoperative 5-fluorouracil: four-year follow-up findings. J Glaucoma. 1999;8(2):124–8. [PubMed: 10209729]
35.
Eliezer RN, Kasahara N, Caixeta-Umbelino C, Pinheiro RK, Mandia C Jr, Malta RF. Use of amniotic membrane in trabeculectomy for the treatment of glaucoma: a pilot study. Arq Bras Oftalmol. 2006;69(3):309–12. [PubMed: 16936950]
36.
Hyman LG, Komaroff E, Heijl A, Bengtsson B, Leske MC. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005;112(9):1505–13. [PubMed: 16019074]
37.
Evans DW, Bartlett JD, Houde B, Than TP, Shaikh A. Latanoprost-induced stabilization of central visual function in patients with primary open-angle glaucoma. J Ocul Pharmacol Ther. 2008;24(2):224–9. [PubMed: 18355134]
38.
Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma: randomized double-masked clinical trial. J Cataract Refract Surg. 2010;36(3):407–12. [PubMed: 20202537]
39.
Flammer J, Kitazawa Y, Bonomi L, et al. Influence of carteolol and timolol on IOP an visual fields in glaucoma: a multi-center, double-masked, prospective study. Eur J Ophthalmol. 1992;2(4):169–74. [PubMed: 1490088]
40.
Frenkel RE, Shin DH, Epstein DL, Hertzmark E, Bohn JL, Hong YJ. Laser trabeculoplasty: how little is enough? Ophthalmic Surg Lasers. 1997;28(11):900–4. [PubMed: 9387175]
41.
Goldenfeld M, Melamed S, Simon G, Ben Simon GJ. Titanium:sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma. Ophthalmic Surg Lasers Imaging. 2009;40(3):264–9. [PubMed: 19485290]
42.
Halpern MT, Covert DW, Robin AL. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc. 2002;100:109–17. discussion 117–8. [PMC free article: PMC1358952] [PubMed: 12545683]
43.
Heijl A, Bengtsson B. Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial. Graefes Arch Clin Exp Ophthalmol. 2000;238(11):877–83. [PubMed: 11148810]
44.
Herman DC, Gordon MO, Beiser JA, et al. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol. 2006;142(5):800–10. [PMC free article: PMC1976472] [PubMed: 17056362]
45.
Javitt JC, Schiffman RM. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. J Glaucoma. 2000;9(3):224–34. [PubMed: 10877373]
46.
Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease. Eye (Lond). 1989;3(Pt 5):528–35. [PubMed: 2698360]
47.
Kaplan-Messas A, Cohen Y, Blumenthal E, Avni I. Trabeculectomy and phaco-trabeculectomy with and without peripheral iridectomy. Eur J Ophthalmol. 2009;19(2):231–4. [PubMed: 19253239]
48.
Kim YY, Sexton RM, Shin DH, et al. Outcomes of primary phakic trabeculectomies without versus with 0.5- to 1-minute versus 3- to 5-minute mitomycin C. Am J Ophthalmol. 1998;126(6):755–62. [PubMed: 9859998]
49.
Kobayashi H, Kobayashi K. A comparison of the intraocular pressure lowering effect of adjustable suture versus laser suture lysis for trabeculectomy. J Glaucoma. 2011;20(4):228–33. [PubMed: 20577111]
50.
Kobayashi H, Kobayashi K. A Comparison of the Intraocular Pressure Lowering Effect of Adjustable Suture Versus Laser Suture Lysis for Trabeculectomy. J Glaucoma. 2010 [PubMed: 20577111]
51.
Kobayashi H, Kobayashi K. Randomized comparison of the intraocular pressure-lowering effect of phacoviscocanalostomy and phacotrabeculectomy. Ophthalmology. 2007;114(5):909–14. [PubMed: 17397924]
52.
Konstas AG, Kozobolis VP, Tersis I, Leech J, Stewart WC. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye (Lond). 2003;17(1):41–6. [PubMed: 12579169]
53.
Kozobolis VP, Siganos CS, Christodoulakis EV, Lazarov NP, Koutentaki MG, Pallikaris IG. Two-site phacotrabeculectomy with intraoperative mitomycin-C: fornix- versus limbus-based conjunctival opening in fellow eyes. J Cataract Refract Surg. 2002;28(10):1758–62. [PubMed: 12388024]
54.
Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151(4):671–81. [PubMed: 21257146]
55.
Lai JS, Chua JK, Tham CC, Lam DS. Five-year follow up of selective laser trabeculoplasty in Chinese eyes. Clin Experiment Ophthalmol. 2004;32(4):368–72. [PubMed: 15281969]
56.
Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001;108(8):1439–44. [PubMed: 11470697]
57.
Liu CJ, Ko YC, Cheng CY, et al. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Ophthalmology. 2002;109(12):2241–7. [PubMed: 12466165]
58.
Macky TA. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study. J Ocul Pharmacol Ther. 2010;26(6):605–10. [PubMed: 21034177]
59.
Marcon IM. A double-masked comparison of betaxolol and levobunolol for the treatment of primary open-angle glaucoma. Arquivos Brasileiros De Oftalmologia. 1990;53(1):27–32.
60.
Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther. 2000;22(1):103–11. [PubMed: 10688394]
61.
Martínez A, Sanchez-Salorio M. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. Acta Ophthalmologica. 2010;88(5):541–52. [PubMed: 19799592]
62.
Messmer C, Flammer J, Stumpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol. 1991;112(6):678–81. [PubMed: 1957903]
63.
Mielke C, Dawda VK, Anand N. Deep sclerectomy and low dose mitomycin C: a randomised prospective trial in west Africa. Br J Ophthalmol. 2006;90(3):310–3. [PMC free article: PMC1856941] [PubMed: 16488952]
64.
Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112(3):366–75. [PubMed: 15745761]
65.
Mirza GE, Karakucuk S, Temel E. Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. J Glaucoma. 2000;9(1):45–50. [PubMed: 10708231]
66.
Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J Ophthalmol. 1997;123(4):465–77. [PubMed: 9124243]
67.
Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113(2):239–46. [PubMed: 16458092]
68.
Pfeiffer N. Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2011;249(7):1065–71. [PubMed: 21499770]
69.
Prata TS, Piassi MV, Melo LA Jr. Changes in visual function after intraocular pressure reduction using antiglaucoma medications. Eye (Lond). 2009;23(5):1081–5. [PubMed: 18670465]
70.
Quaranta L, Pizzolante T, Riva I, Haidich AB, Konstas AG, Stewart WC. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol. 2008;92(9):1227–31. [PubMed: 18586898]
71.
Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47(7):2917–23. [PubMed: 16799034]
72.
Quaranta L, Bettelli S, Gandolfo E. Efficacy of sulodexide as adjunct in trabeculectomy. A two-year randomized clinical study. Acta Ophthalmol Scand Suppl. 2000;(232):63–5. [PubMed: 11235544]
73.
Rainer G, Dorner GT, Garhofer G, Vass C, Pfleger T, Schmetterer L. Changing antiglaucoma therapy from timolol to betaxolol: effect on ocular blood flow. Ophthalmologica. 2003;217(4):288–93. [PubMed: 12792136]
74.
Ravalico G, Salvetat L, Toffoli G, Pastori G, Croce M, Battaglia Parodi M. Ocular hypertension: A follow-up study in treated and untreated patients. NEW TRENDS OPHTHALMOL. 1994;9(2):97–101.
75.
Reibaldi A, Uva MG, Longo A. Nine-year follow-up of trabeculectomy with or without low-dosage mitomycin-c in primary open-angle glaucoma. Br J Ophthalmol. 2008;92(12):1666–70. [PubMed: 18782799]
76.
Rosentreter A, Schild AM, Jordan JF, Krieglstein GK, Dietlein TS. A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma. Eye (Lond). 2010;24(9):1449–57. [PubMed: 20733558]
77.
Russo V, Barone A, Cosma A, Stella A, Delle Noci N. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with uncontrolled open-angle glaucoma. Eur J Ophthalmol. 2009;19(3):429–34. [PubMed: 19396790]
78.
Russo V, Scott IU, Stella A, et al. Nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant versus punch trabeculectomy: a prospective clinical trial. Eur J Ophthalmol. 2008;18(5):751–7. [PubMed: 18850554]
79.
Sanders R, MacEwen CJ, Haining WM. Trabeculectomy: effect of varying surgical site. Eye (Lond). 1993;7(Pt 3):440–3. [PubMed: 8224303]
80.
Sawada A, Yamamoto T, Takatsuka N. Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2011 [PubMed: 21858678]
81.
Schenker H, Maloney S, Liss C, Gormley G, Hartenbaum D. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin Ther. 1999;21(1):138–47. [PubMed: 10090431]
82.
Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: A controlled, randomized, multicenter clinical trial. ARCH. OPHTHALMOL. 1997;115(7):847–52. [PubMed: 9230823]
83.
Scoville B, Mueller B, White BG, Krieglstein GK. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol. 1988;105(2):150–4. [PubMed: 3277436]
84.
Shaarawy T, Mermoud A. Deep sclerectomy in one eye vs deep sclerectomy with collagen implant in the contralateral eye of the same patient: long-term follow-up. Eye (Lond). 2005;19(3):298–302. [PubMed: 15258610]
85.
Sharpe ED, Day DG, Beischel CJ, Rhodes JS, Stewart JA, Stewart WC. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2004;88(7):953–6. [PMC free article: PMC1772220] [PubMed: 15205246]
86.
Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44(Suppl 2):S163–8. [PubMed: 10665519]
87.
Shuster JN, Krupin T, Kolker AE, Becker B. Limbus- v fornix-based conjunctival flap in trabeculectomy. A long-term randomized study. Arch Ophthalmol. 1984;102(3):361–2. [PubMed: 6703982]
88.
Singh K, Byrd S, Egbert PR, Budenz D. Risk of hypotony after primary trabeculectomy with antifibrotic agents in a black west African population. J Glaucoma. 1998;7(2):82–5. [PubMed: 9559492]
89.
Solish AM, DeLucca PT, Cassel DA, Kolodny AH, Hustad CM, Skobieranda F. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma. 2004;13(2):149–57. [PubMed: 15097262]
90.
Tang M, Fu Y, Fu MS, et al. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surg Lasers Imaging. 2011;42(1):59–63. [PubMed: 21117578]
91.
Thimmarayan SK, Rao VA, Gupta A. Mini-trabeculectomy in comparison to conventional trabeculectomy in primary open angle glaucoma. Eur J Ophthalmol. 2006;16(5):674–9. [PubMed: 17061217]
92.
Tressler CS, Cyrlin MN, Rosenshein JS, Fazio R. Subconjunctival versus intrascleral mitomycin-C in trabeculectomy. Ophthalmic Surg Lasers. 1996;27(8):661–6. [PubMed: 8858631]
93.
Tuulonen A, Koponen J, Alanko HI, Airaksinen PJ. Laser trabeculoplasty versus medication treatment as primary therapy for glaucoma. Acta Ophthalmol (Copenh). 1989;67(3):275–80. [PubMed: 2669435]
94.
Vainio-Jylha E, Vuori ML. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 1999;237(2):100–4. [PubMed: 9987624]
95.
Yamamoto T, Kitazawa Y, Noma A, et al. The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J Glaucoma. 1996;5(4):252–7. [PubMed: 8795770]
96.
Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma. 2008;17(1):36–9. [PubMed: 18303382]
97.
Yuksel N, Gok M, Altintas O, Caglar Y. Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma. Curr Eye Res. 2011;36(9):804–8. [PubMed: 21851166]
98.
Montemayor F, Sibley LM, Courtright P, Mikelberg FS. Contribution of multiple glaucoma medications to visual function and quality of life in patients with glaucoma. Can J Ophthalmol. 2001;36(7):385–90. [PubMed: 11794387]
99.
Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122(7):957–65. [PubMed: 15249358]
100.
Arici MK, Arici DS, Topalkara A, Guler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Experiment Ophthalmol. 2000;28(2):113–7. [PubMed: 10933774]
101.
Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO. The incidence of retinal vein occlusion in the ocular hypertension treatment study. Ophthalmology. 2010;117(3):484–8. [PMC free article: PMC3077045] [PubMed: 20031222]
102.
Chiselita D. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients. Oftalmologia. 2007;51(2):81–6. [PubMed: 17937041]
103.
Denis P, Baudouin C, Bron A, et al. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010;10:4. [PMC free article: PMC2841111] [PubMed: 20181282]
104.
Farris EP. Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital. Clin Ophthalmol. 2008;2(2):303–12. [PMC free article: PMC2693979] [PubMed: 19668721]
105.
Jeganathan VS, Ghosh S, Ruddle JB, Gupta V, Coote MA, Crowston JG. Risk factors for delayed suprachoroidal haemorrhage following glaucoma surgery. Br J Ophthalmol. 2008;92(10):1393–6. [PubMed: 18684750]
106.
Kobayashi H, Kobayashi K. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect. J Glaucoma. 2011;20(1):3–6. [PubMed: 20520573]
107.
Renieri G, Fuhrer K, Scheithe K, Lorenz K, Pfeiffer N, Thieme H. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients. J Ocul Pharmacol Ther. 2010;26(6):597–603. [PubMed: 20977366]
108.
Schwartz GF, Kotak S, Mardekian J, Fain JM. Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: Retrospective analysis of three medical/pharmacy claims databases. BMC Ophthalmol. 2011;11:14. [PMC free article: PMC3146461] [PubMed: 21672240]
109.
Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 2007;32(12):1037–43. [PubMed: 18085467]
110.
Shingleton BJ, Chaudhry IM, O’Donoghue MW. Phacotrabeculectomy: peripheral iridectomy or no peripheral iridectomy? J Cataract Refract Surg. 2002;28(6):998–1002. [PubMed: 12036643]
111.
Thelen U, Christ T, Schnober D, Hofstetter HJ, Stewart WC. Midterm response with latanoprost therapy in german ocular hypertension patients. Curr Eye Res. 2007;32(1):51–6. [PubMed: 17364735]
112.
Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol. 2000;84(7):710–3. [PMC free article: PMC1723530] [PubMed: 10873979]
113.
Zimmerman TJ, Stewart WC. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19(5):405–15. [PubMed: 14583133]
114.
Nassiri N, Nassiri N, Rahnavardi M, Rahmani L. A comparison of corneal endothelial cell changes after 1-site and 2-site phacotrabeculectomy. Cornea. 2008;27(8):889–94. [PubMed: 18724149]
115.
Janz NK, Wren PA, Guire KE, Musch DC, Gillespie BW, Lichter PR. Fear of blindness in the Collaborative Initial Glaucoma Treatment Study: patterns and correlates over time. Ophthalmology. 2007;114(12):2213–20. [PubMed: 17490746]
116.
Janz NK, Wren PA, Lichter PR, et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108(11):1954–65. [PubMed: 11713062]
117.
Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology. 2002;109(2):307–14. discussion 314–5. [PubMed: 11825814]
118.
Cantor LB, Hoop J, Katz LJ, Flartey K. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure. Clin Ther. 2001;23(7):1032–9. [PubMed: 11519768]
119.
Javitt J, Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. J Glaucoma. 2000;9(5):398–408. [PubMed: 11039742]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (21M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...